29.12.2021 Views

Diagnostic ultrasound ( PDFDrive )

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

CHAPTER 51 The Pediatric Liver and Spleen 1749

A1

A2

B

FIG. 51.18 Biliary Rhabdomyosarcoma in 3-Year-Old

Child. (A1) and (A2) Transverse and longitudinal sonograms of

porta hepatis in child with intermittent jaundice and abdominal

pain show an intraductal mass enlarging the common bile duct

between the cursors. (B) Coronal T1-weighted magnetic resonance

image demonstrating the intraductal mass (arrow) and secondary

biliary ductal dilation.

ultrasound coupled to a spectral or color Doppler display are

discussed in Chapter 1.

Most of the abdominal vessels studied in children have a low

low velocity. herefore the wall ilter should be as low as possible,

preferably at 50 Hz or less. he pulse repetition frequency should

be as low as possible for the same reason, unless there is

aliasing.

here are great advantages to color mapping (Video 51.7)

because entire segments of vessels are seen at a glance (e.g.,

portosystemic collateral veins in portal hypertension or stenoses

of vessels). When examining small vessels in children, motion

may produce lashes or dots of color artifact. Pulsed Doppler

sampling of such doubtful signals distinguishes these artifacts

from low signals. Because of their small body size and ready

access to the Doppler beam, children are particularly suited to

color, power, and pulsed Doppler abdominal examinations.

New Doppler techniques that are more sensitive to low-velocity

low, which was previously obscured by noise or “signal clutter,”

have the potential to reveal isoechoic lesions in the liver, including

metastases. Superb microvascular imaging shows third- and

fourth-order branches of the portal veins 56 (Fig. 51.21, Video

51.8, Video 51.9). SMI takes the same returning ultrasound signal

and declutters the information to depict very-low-velocity low.

Intravenous Doppler contrast agents, various formulations of

microbubbles, are now approved by the U.S. Food and Drug

Administration (FDA) for cardiac and liver use in the United

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!